Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: Molecular basis for therapeutic implications

Cytokine and Growth Factor Reviews

Volumn 23, Issue 6, 2012, Pages 343-356

  Kong, Xiangyu ^a   Li, Lei ^a   Li, Zhaoshen ^a   Xie, Keping ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cytokines; Growth factors; Immunology; Therapy; Transcriptional factors

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AXITINIB; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYCLOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEMCITABINE; LY 2157299; MARIMASTAT; MICRORNA; OSTEONECTIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; RANTES; SARIDEGIB; SCATTER FACTOR RECEPTOR; SMAD4 PROTEIN; SONIC HEDGEHOG PROTEIN; SORAFENIB; TANOMASTAT; TIVANTINIB; TRABEDERSEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL TRANSDIFFERENTIATION; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG TARGETING; DRUG TUMOR LEVEL; ENDOSCOPIC ECHOGRAPHY; EPITHELIAL MESENCHYMAL TRANSITION; HISTOPATHOLOGY; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MESENCHYMAL STEM CELL; MONOTHERAPY; MUCINOUS CYSTIC NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PANCREAS ADENOMA; PANCREAS CANCER; PANCREAS CYST; PANCREAS RESECTION; PANCREAS STROMA; PANCREATITIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; TUMOR PROMOTION; TUMOR VASCULARIZATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; PANCREAS; PANCREATIC NEOPLASMS; STROMAL CELLS;

ANIMALIA;

EID: 84869871096     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.06.006     Document Type: Review

References (150)

1. Huang C., Xie K. Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine & Growth Factor Reviews 2012, 23:25-35.
2. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians 2011, 61:212-236.
3. Xie K., Wei D., Huang S. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine & Growth Factor Reviews 2006, 17:147-156.
4. Haddad A., Kowdley G.C., Pawlik T.M., Cunningham S.C. Hereditary pancreatic and hepatobiliary cancers. International Journal of Surgery and Oncology 2011, 2011:154673.
5. Brentnall T.A. Management strategies for patients with hereditary pancreatic cancer. Current Treatment Options in Oncology 2005, 6:437-445.
6. Kimura W., Kuroda A., Makuuchi M. Problems in the diagnosis and treatment of a so-called mucin-producing tumor of the pancreas. Pancreas 1998, 16:363-369.
7. Neesse A., Michl P., Frese K.K., Feig C., Cook N., Jacobetz M.A., et al. Stromal biology and therapy in pancreatic cancer. Gut 2011, 60:861-868.
8. Chu G.C., Kimmelman A.C., Hezel A.F., DePinho R.A. Stromal biology of pancreatic cancer. Journal of Cellular Biochemistry 2007, 101:887-907.
9. McCleary-Wheeler A.L., McWilliams R., Fernandez-Zapico M.E. Aberrant signaling pathways in pancreatic cancer: a two compartment view. Molecular Carcinogenesis 2012, 51:25-39.
10. Brugge W.R., Lauwers G.Y., Sahani D., Fernandez-del Castillo C., Warshaw A.L. Cystic neoplasms of the pancreas. The New England Journal of Medicine 2004, 351:1218-1226.
11. Maitra A., Fukushima N., Takaori K., Hruban R.H. Precursors to invasive pancreatic cancer. Advances in Anatomic Pathology 2005, 12:81-91.
12. Bardeesy N., DePinho R.A. Pancreatic cancer biology and genetics. Nature Reviews. Cancer 2002, 2:897-909.
13. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., et al. Genetic alterations during colorectal-tumor development. The New England Journal of Medicine 1988, 319:525-532.
14. Heinmoller E., Dietmaier W., Zirngibl H., Heinmoller P., Scaringe W., Jauch K.W., et al. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. The American Journal of Pathology 2000, 157:83-92.
15. Yamano M., Fujii H., Takagaki T., Kadowaki N., Watanabe H., Shirai T. Genetic progression and divergence in pancreatic carcinoma. The American Journal of Pathology 2000, 156:2123-2133.
16. Klimstra D.S., Longnecker D.S. K-ras mutations in pancreatic ductal proliferative lesions. The American Journal of Pathology 1994, 145:1547-1550.
17. Rozenblum E., Schutte M., Goggins M., Hahn S.A., Panzer S., Zahurak M., et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Research 1997, 57:1731-1734.
18. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
19. Folkman J., Kalluri R. Cancer without disease. Nature 2004, 427:787.
20. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews 1989, 8:98-101.
21. Birnstingl M. A study of pancreatography. The British Journal of Surgery 1959, 47:128-139.
22. Kozuka S., Sassa R., Taki T., Masamoto K., Nagasawa S., Saga S., et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer 1979, 43:1418-1428.
23. Petersen O.W., Ronnov-Jessen L., Howlett A.R., Bissell M.J. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:9064-9068.
24. Froeling F.E., Mirza T.A., Feakins R.M., Seedhar A., Elia G., Hart I.R., et al. Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells. The American Journal of Pathology 2009, 175:636-648.
25. Cousin B., Ravet E., Poglio S., De Toni F., Bertuzzi M., Lulka H., et al. Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. PLoS One 2009, 4:e6278.
26. Kloppel G. Chronic pancreatitis, pseudotumors and other tumor-like lesions. Modern Pathology 2007, 20(Suppl. 1):S113-S131.
27. Whitcomb D.C. Inflammation and cancer V. Chronic pancreatitis and pancreatic cancer. American Journal of Physiology. Gastrointestinal and Liver Physiology 2004, 287:G315-G319.
28. Malka D., Hammel P., Maire F., Rufat P., Madeira I., Pessione F., et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002, 51:849-852.
29. Whitcomb D.C., Pogue-Geile K. Pancreatitis as a risk for pancreatic cancer. Gastroenterology Clinics of North America 2002, 31:663-678.
30. Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148:349-361.
31. Whitcomb D.C., Gorry M.C., Preston R.A., Furey W., Sossenheimer M.J., Ulrich C.D., et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nature Genetics 1996, 14:141-145.
32. Hwang R.F., Moore T., Arumugam T., Ramachandran V., Amos K.D., Rivera A., et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Research 2008, 68:918-926.
33. Xu Z., Vonlaufen A., Phillips P.A., Fiala-Beer E., Zhang X., Yang L., et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. The American Journal of Pathology 2010, 177:2585-2596.
34. Kelsen D.P., Portenoy R., Thaler H., Tao Y., Brennan M. Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Surgery 1997, 122:53-59.
35. Pelaez-Luna M., Takahashi N., Fletcher J.G., Chari S.T. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. The American Journal of Gastroenterology 2007, 102:2157-2163.
36. Slaga T.J. Overview of tumor promotion in animals. Environmental Health Perspectives 1983, 50:3-14.
37. Szafranska A.E., Doleshal M., Edmunds H.S., Gordon S., Luttges J., Munding J.B., et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clinical Chemistry 2008, 54:1716-1724.
38. Li A., Omura N., Hong S.M., Vincent A., Walter K., Griffith M., et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Research 2010, 70:5226-5237.
39. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
40. Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., et al. Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. Journal of Cellular and Molecular Medicine 2008, 12:2823-2835.
41. Binkley C.E., Zhang L., Greenson J.K., Giordano T.J., Kuick R., Misek D., et al. The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas 2004, 29:254-263.
42. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
43. Studeny M., Marini F.C., Dembinski J.L., Zompetta C., Cabreira-Hansen M., Bekele B.N., et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. Journal of the National Cancer Institute 2004, 96:1593-1603.
44. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J., Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Research 2002, 62:3603-3608.
45. Kallifatidis G., Beckermann B.M., Groth A., Schubert M., Apel A., Khamidjanov A., et al. Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer. Cancer Gene Therapy 2008, 15:231-240.
46. Ghaedi M., Soleimani M., Taghvaie N.M., Sheikhfatollahi M., Azadmanesh K., Lotfi A.S., et al. Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors. The Journal of Gene Medicine 2011, 13:171-180.
47. Ronnov-Jessen L., Petersen O.W., Koteliansky V.E., Bissell M.J. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. The Journal of Clinical Investigation 1995, 95:859-873.
48. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nature Reviews. Molecular Cell Biology 2002, 3:349-363.
49. Udagawa T., Puder M., Wood M., Schaefer B.C., D'Amato R.J. Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. The FASEB Journal 2006, 20:95-102.
50. Ogawa M., LaRue A.C., Drake C.J. Hematopoietic origin of fibroblasts/myofibroblasts: its pathophysiologic implications. Blood 2006, 108:2893-2896.
51. Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4:e4992.
52. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Research 2005, 65:3307-3318.
53. Hung S.C., Deng W.P., Yang W.K., Liu R.S., Lee C.C., Su T.C., et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clinical Cancer Research 2005, 11:7749-7756.
54. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
55. Faouzi S., Le Bail B., Neaud V., Boussarie L., Saric J., Bioulac-Sage P., et al. Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. Journal of Hepatology 1999, 30:275-284.
56. Powell D.W., Mifflin R.C., Valentich J.D., Crowe S.E., Saada J.I., West A.B. Myofibroblasts. I. Paracrine cells important in health and disease. American Journal of Physiology 1999, 277:C1-C9.
57. Phan S.H. The myofibroblast in pulmonary fibrosis. Chest 2002, 122:286S-289S.
58. Desmouliere A., Darby I.A., Gabbiani G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Laboratory Investigation: a Journal of Technical Methods and Pathology 2003, 83:1689-1707.
59. Petersen O.W., Nielsen H.L., Gudjonsson T., Villadsen R., Rank F., Niebuhr E., et al. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. The American Journal of Pathology 2003, 162:391-402.
60. Lee E.H., Joo C.K. Role of transforming growth factor-beta in transdifferentiation and fibrosis of lens epithelial cells. Investigative Ophthalmology & Visual Science 1999, 40:2025-2032.
61. Oldfield M.D., Bach L.A., Forbes J.M., Nikolic-Paterson D., McRobert A., Thallas V., et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). The Journal of Clinical Investigation 2001, 108:1853-1863.
62. Li J.H., Wang W., Huang X.R., Oldfield M., Schmidt A.M., Cooper M.E., et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. The American Journal of Pathology 2004, 164:1389-1397.
63. Nightingale J., Patel S., Suzuki N., Buxton R., Takagi K.I., Suzuki J., et al. Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation. Journal of the American Society of Nephrology 2004, 15:21-32.
64. Willis B.C., Liebler J.M., Luby-Phelps K., Nicholson A.G., Crandall E.D., du Bois R.M., et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. The American Journal of Pathology 2005, 166:1321-1332.
65. Kim K.K., Kugler M.C., Wolters P.J., Robillard L., Galvez M.G., Brumwell A.N., et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:13180-13185.
66. Selman M., Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proceedings of the American Thoracic Society 2006, 3:364-372.
67. Gudjonsson T., Adriance M.C., Sternlicht M.D., Petersen O.W., Bissell M.J. Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. Journal of Mammary Gland Biology and Neoplasia 2005, 10:261-272.
68. Moinfar F., Man Y.G., Arnould L., Bratthauer G.L., Ratschek M., Tavassoli F.A. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Research 2000, 60:2562-2566.
69. Folkman J. Role of angiogenesis in tumor growth and metastasis. Seminars in Oncology 2002, 29:15-18.
70. Folkman J. Fundamental concepts of the angiogenic process. Current Molecular Medicine 2003, 3:643-651.
71. Folkman J. What is the evidence that tumors are angiogenesis dependent?. Journal of the National Cancer Institute 1990, 82:4-6.
72. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K.E., Geber A., et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
73. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
74. Kordes C., Brookmann S., Haussinger D., Klonowski-Stumpe H. Differential and synergistic effects of platelet-derived growth factor-BB and transforming growth factor-beta1 on activated pancreatic stellate cells. Pancreas 2005, 31:156-167.
75. Vogelmann R., Ruf D., Wagner M., Adler G., Menke A. Effects of fibrogenic mediators on the development of pancreatic fibrosis in a TGF-beta1 transgenic mouse model. American Journal of Physiology. Gastrointestinal and Liver Physiology 2001, 280:G164-G172.
76. Lohr M., Schmidt C., Ringel J., Kluth M., Muller P., Nizze H., et al. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Research 2001, 61:550-555.
77. Bardeesy N., Cheng K.H., Berger J.H., Chu G.C., Pahler J., Olson P., et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes & Development 2006, 20:3130-3146.
78. Duda D.G., Sunamura M., Lefter L.P., Furukawa T., Yokoyama T., Yatsuoka T., et al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 2003, 22:6857-6864.
79. Schwarte-Waldhoff I., Volpert O.V., Bouck N.P., Sipos B., Hahn S.A., Klein-Scory S., et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:9624-9629.
80. Aoki H., Ohnishi H., Hama K., Shinozaki S., Kita H., Osawa H., et al. Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines. American Journal of Physiology. Cell Physiology 2007, 292:C259-C268.
81. Hoch R.V., Soriano P. Roles of PDGF in animal development. Development 2003, 130:4769-4784.
82. Blaine S.A., Ray K.C., Branch K.M., Robinson P.S., Whitehead R.H., Means A.L. Epidermal growth factor receptor regulates pancreatic fibrosis. American Journal of Physiology. Gastrointestinal and Liver Physiology 2009, 297:G434-G441.
83. Dong J., Grunstein J., Tejada M., Peale F., Frantz G., Liang W.C., et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. The EMBO Journal 2004, 23:2800-2810.
84. Yu J., Liu X.W., Kim H.R. Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun NH2-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of p53. The Journal of Biological Chemistry 2003, 278:49582-49588.
85. Xie K., Abbruzzese J.L. Developmental biology informs cancer: the emerging role of the hedgehog signaling pathway in upper gastrointestinal cancers. Cancer Cell 2003, 4:245-247.
86. Teglund S., Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochimica et Biophysica Acta 2010, 1805:181-208.
87. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
88. Berman D.M., Karhadkar S.S., Maitra A., Montes De Oca R., Gerstenblith M.R., Briggs K., et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425:846-851.
89. Feldmann G., Dhara S., Fendrich V., Bedja D., Beaty R., Mullendore M., et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Research 2007, 67:2187-2196.
90. Yauch R.L., Gould S.E., Scales S.J., Tang T., Tian H., Ahn C.P., et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455:406-410.
91. Tian H., Callahan C.A., DuPree K.J., Darbonne W.C., Ahn C.P., Scales S.J., et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:4254-4259.
92. Bailey J.M., Swanson B.J., Hamada T., Eggers J.P., Singh P.K., Caffery T., et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clinical Cancer Research 2008, 14:5995-6004.
93. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
94. van Niel G., Porto-Carreiro I., Simoes S., Raposo G. Exosomes: a common pathway for a specialized function. Journal of Biochemistry 2006, 140:13-21.
95. Johnstone R.M. The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochemistry and Cell Biology 1992, 70:179-190.
96. Baj-Krzyworzeka M., Szatanek R., Weglarczyk K., Baran J., Urbanowicz B., Branski P., et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunology, Immunotherapy: CII 2006, 55:808-818.
97. Dolo V., D'Ascenzo S., Violini S., Pompucci L., Festuccia C., Ginestra A., et al. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clinical & Experimental Metastasis 1999, 17:131-140.
98. Ginestra A., La Placa M.D., Saladino F., Cassara D., Nagase H., Vittorelli M.L. The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Research 1998, 18:3433-3437.
99. Tsui N.B., Ng E.K., Lo Y.M. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clinical Chemistry 2002, 48:1647-1653.
100. Reddi K.K., Holland J.F. Elevated serum ribonuclease in patients with pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America 1976, 73:2308-2310.
101. Kong X., Du Y., Wang G., Gao J., Gong Y., Li L., et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Digestive Diseases and Sciences 2011, 56:602-609.
102. Liu J., Gao J., Du Y., Li Z., Ren Y., Gu J., et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. International Journal of Cancer 2011, 131:683-691.
103. Muralidharan-Chari V., Clancy J.W., Sedgwick A., D'Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. Journal of Cell Science 2010, 123:1603-1611.
104. Grange C., Tapparo M., Collino F., Vitillo L., Damasco C., Deregibus M.C., et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Research 2011, 71:5346-5356.
105. Sultana A., Tudur Smith C., Cunningham D., Starling N., Tait D., Neoptolemos J.P., et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. British Journal of Cancer 2007, 96:1183-1190.
106. Huguet F., Andre T., Hammel P., Artru P., Balosso J., Selle F., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. Journal of Clinical Oncology 2007, 25:326-331.
107. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology 1997, 15:2403-2413.
108. Ueda S., Ogata S., Tsuda H., Kawarabayashi N., Kimura M., Sugiura Y., et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004, 29:e1-e8.
109. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 2007, 25:1960-1966.
110. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine 2004, 350:2335-2342.
111. Kindler H.L., Niedzwiecki D., Hollis D., Sutherland S., Schrag D., Hurwitz H., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). Journal of Clinical Oncology 2010, 28:3617-3622.
112. Van Cutsem E., Vervenne W.L., Bennouna J., Humblet Y., Gill S., Van Laethem J.L., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Journal of Clinical Oncology 2009, 27:2231-2237.
113. Bramhall S.R., Neoptolemos J.P., Stamp G.W., Lemoine N.R. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. The Journal of Pathology 1997, 182:347-355.
114. Bramhall S.R., Rosemurgy A., Brown P.D., Bowry C., Buckels J.A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. Journal of Clinical Oncology 2001, 19:3447-3455.
115. Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., Buckels J.A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. British Journal of Cancer 2002, 87:161-167.
116. Moore M.J., Hamm J., Dancey J., Eisenberg P.D., Dagenais M., Fields A., et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 2003, 21:3296-3302.
117. Levy L., Hill C.S. Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Molecular and Cellular Biology 2005, 25:8108-8125.
118. Melisi D., Ishiyama S., Sclabas G.M., Fleming J.B., Xia Q., Tortora G., et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Molecular Cancer Therapeutics 2008, 7:829-840.
119. Medicherla S., Li L., Ma J.Y., Kapoun A.M., Gaspar N.J., Liu Y.W., et al. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. Anticancer Research 2007, 27:4149-4157.
120. Schlingensiepen K.H., Schlingensiepen R., Steinbrecher A., Hau P., Bogdahn U., Fischer-Blass B., et al. Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine & Growth Factor Reviews 2006, 17:129-139.
121. Hu W.G., Liu T., Xiong J.X., Wang C.Y. Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. Acta Pharmacologica Sinica 2007, 28:1224-1230.
122. Furukawa T., Duguid W.P., Kobari M., Matsuno S., Tsao M.S. Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. The American Journal of Pathology 1995, 147:889-895.
123. Infante J.R., Matsubayashi H., Sato N., Tonascia J., Klein A.P., Riall T.A., et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. Journal of Clinical Oncology 2007, 25:319-325.
124. Nyman D.W., Campbell K.J., Hersh E., Long K., Richardson K., Trieu V., et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. Journal of Clinical Oncology 2005, 23:7785-7793.
125. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Journal of Clinical Oncology 2011, 29:4548-4554.
126. Pancreatic cancer: paclitaxel stabilizes intratumoural gemcitabine levels. Nat Rev Clin Oncol 2012;9:246.
127. Lee E.J., Gusev Y., Jiang J., Nuovo G.J., Lerner M.R., Frankel W.L., et al. Expression profiling identifies microRNA signature in pancreatic cancer. International Journal of Cancer 2007, 120:1046-1054.
128. Juuti A., Nordling S., Lundin J., Louhimo J., Haglund C. Syndecan-1 expression - a novel prognostic marker in pancreatic cancer. Oncology 2005, 68:97-106.
129. Bloomston M., Ellison E.C., Muscarella P., Al-Saif O., Martin E.W., Melvin W.S., et al. Stromal osteonectin overexpression is associated with poor outcome in patients with ampullary cancer. Annals of Surgical Oncology 2007, 14:211-217.
130. Mantoni T.S., Schendel R.R., Rodel F., Niedobitek G., Al-Assar O., Masamune A., et al. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biology & Therapy 2008, 7:1806-1815.
131. Fukushima N., Kikuchi Y., Nishiyama T., Kudo A., Fukayama M. Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Modern Pathology 2008, 21:1044-1053.
132. Erkan M., Michalski C.W., Rieder S., Reiser-Erkan C., Abiatari I., Kolb A., et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clinical Gastroenterology and Hepatology 2008, 6:1155-1161.
133. Ohlund D., Lundin C., Ardnor B., Oman M., Naredi P., Sund M. Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. British Journal of Cancer 2009, 101:91-97.
134. Okada K., Hirabayashi K., Imaizumi T., Matsuyama M., Yazawa N., Dowaki S., et al. Stromal thrombospondin-1 expression is a prognostic indicator and a new marker of invasiveness in intraductal papillary-mucinous neoplasm of the pancreas. Biomedical Research 2010, 31:13-19.
135. Scaife C.L., Shea J., Emerson L., Boucher K., Firpo M.A., Beckerle M.C., et al. Prognostic significance of PINCH signalling in human pancreatic ductal adenocarcinoma. HPB (Oxford) 2010, 12:352-358.
136. Hiraoka N., Onozato K., Kosuge T., Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clinical Cancer Research 2006, 12:5423-5434.
137. Hrabar D., Aralica G., Gomercic M., Ljubicic N., Kruslin B., Tomas D. Epithelial and stromal expression of syndecan-2 in pancreatic carcinoma. Anticancer Research 2010, 30:2749-2753.
138. Ikenaga N., Ohuchida K., Mizumoto K., Cui L., Kayashima T., Morimatsu K., et al. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology 2010, 139:1041-1051. 51 e1-e8.
139. De Monte L., Reni M., Tassi E., Clavenna D., Papa I., Recalde H., et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. The Journal of Experimental Medicine 2011, 208:469-478.
140. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
141. Heid I., Lubeseder-Martellato C., Sipos B., Mazur P.K., Lesina M., Schmid R.M., et al. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology 2011, 141:719-730. 30 e1-e7.
142. Ijichi H., Chytil A., Gorska A.E., Aakre M.E., Bierie B., Tada M., et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. The Journal of Clinical Investigation 2011, 121:4106-4117.
143. Tjomsland V., Niklasson L., Sandstrom P., Borch K., Druid H., Bratthall C., et al. The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clinical & Developmental Immunology 2011, 2011:212810.
144. Brentnall T.A., Lai L.A., Coleman J., Bronner M.P., Pan S., Chen R. Arousal of cancer-associated stroma: overexpression of palladin activates fibroblasts to promote tumor invasion. PLoS One 2012, 7:e30219.
145. Balaz P., Friess H., Kondo Y., Zhu Z., Zimmermann A., Buchler M.W. Human macrophage metalloelastase worsens the prognosis of pancreatic cancer. Annals of Surgery 2002, 235:519-527.
146. Yuzawa S., Kano M.R., Einama T., Nishihara H. PDGFRbeta expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker. Medical Oncology 2012, 10.1007/s12032-012-0193-0.
147. Koopmann J., Fedarko N.S., Jain A., Maitra A., Iacobuzio-Donahue C., Rahman A., et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiology, Biomarkers & Prevention 2004, 13:487-491.
148. Seo Y., Baba H., Fukuda T., Takashima M., Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000, 88:2239-2245.
149. Kindler H.L., Ioka T., Richel D.J., Bennouna J., Letourneau R., Okusaka T., et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. The Lancet Oncology 2011, 12:256-262.
150. Philip P.A., Benedetti J., Corless C.L., Wong R., O'Reilly E.M., Flynn P.J., et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. Journal of Clinical Oncology 2010, 28:3605-3610.